Merck & Co., Inc.
MRK
Below: live stock price for Merck & Co., Inc. (MRK), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Merck & Co., Inc. (MRK) trades at 141.98 USD on cryptosrank.
- Prev close
- $145.45
- Volume (24h)
- $1.19B
- Market cap
- $350.29B
- Currency
- USD
Score
Insufficient data
- Value—
- Quality—
- Momentum—
- Growth—
- Risk—
- Dividend—
- Liquidity—
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 144.4768 +0.95%
- +20 bars
- 146.3803 +2.28%
- +60 bars
- 147.1234 +2.80%
- +120 bars
- 147.1508 +2.82%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0465 USD.
Interpretation
Price sits in the middle of the recent range, trend is sloping upward.
Descriptive observation — not investment advice.
Price report
How this asset has actually moved over the last 252 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 28.8%
- Max drawdown
- -11.9%
- Below period high
- -8.8%
- Best day
- +12.60%
- Worst day
- -4.06%
- Up days
- 51%
- Current streak
- 2 down
- Typical day swing
- 2.4%
- Volume vs average
- -12%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 156.92 high → 124.1 low · 60 bars
- ResistanceFib +161.8% extensionnot reached210.0228 USD+46.75% from current
- ResistanceFib +100% extensionnot reached189.74 USD+32.58% from current
- ResistanceFib +61.8% extensionnot reached177.2028 USD+23.82% from current
- ResistanceFib +27.2% extensionnot reached165.847 USD+15.89% from current
- ResistanceFib 23.6% retracementtested 17×149.1745 USD+4.24% from current
- ResistanceFib 38.2% retracementNearesttested 7×144.3828 USD+0.89% from current
- Current143.1127 USD
- SupportFib 50% midpointtested 3×140.51 USD-1.82% from current
- SupportFib 61.8% retracementtested 2×136.6372 USD-4.52% from current
- SupportFib 78.6% retracementtested 6×131.1235 USD-8.38% from current
- SupportFib −27.2% extensionnot reached115.173 USD-19.52% from current
- SupportFib −61.8% extensionnot reached103.8172 USD-27.46% from current
- SupportFib −100% extensionnot reached91.28 USD-36.22% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Recent news
- Merck (MRK) Dips More Than Broader Market: What You Should KnowZacks2h ago
- What Does Bristol-Myers Squibb Offer That Pfizer Does Not?Trefis3h ago
- What Is Eli Lilly Stock's Biggest Opportunity?Trefis3h ago
- Can a Spinoff Fix Johnson & Johnson’s Medtech Problem?Barrons.com4h ago
- Here’s What’s Dragging Down the DowBarrons.com5h ago
- Merck (MRK) Reports a Negative Operating Margin and Pays Out 266% of Earnings. What Explains Both?Insider Monkey5h ago
- Johnson & Johnson stock falls despite strong earnings as investors focus on medtech unitYahoo Finance6h ago
- BioNTech’s Cancer Drug Misses A Key Trial Goal – Citi Says Survival Data Could Preserve ‘A Meaningful Development Path’Stocktwits6h ago
Related
Other assets in this category.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,551 USD+2.57%
- 7203.TToyota Motor Corporation2,984 USD+2.53%
- 9984.TSoftBank Group Corp.5,310 USD-8.50%
- 6758.TSony Group Corporation3,814 USD+0.00%
- 6861.TKeyence Corporation79,770 USD-0.96%
- NVDANVIDIA Corporation228.52 USD+0.97%
- AAPLApple Inc.341.27 USD+0.09%
- GOOGLAlphabet Inc.353.78 USD+0.30%
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.